Erbitux (cetuximab) / BMS, Eli Lilly, EMD Serono - LARVOL DELTA

Mechanisms of resistance to anti-HER2 therapies in brain metastatic derivatives of inflammatory HER2-positive breast cancer models (SABCS 2025) - "The HER2-selective tyrosine kinase inhibitor (TKI) tucatinib (Tuca) and the pan-HER TKI neratinib (Nrb), mostly used in the late line setting, are effective, including in treating brain metastases...Drug efficacy studies involved methylene blue-based cell growth and IC50 assays, and included the Akt inhibitor (i), capivasertib (Capi, 1uM), T-DXd (5ug/mL), and the EGFR-specific TKI gefitinib (Gef, 1uM) or monoclonal antibody cetuximab (Cetux, 10ug/mL)... Our findings suggest the role of high EGFR and PIK3CA mutations in resistance to Tuca, which warrants additional preclinical and clinical investigation. This underscores the importance of understanding if PIK3CA mutations are associated with reduced Tuca sensitivity and the testing of new mutant specific PIK3CAi or other PI3K/Akt pathway inhibitors. Our brain tropic TucaR cell and mouse models will be useful to understanding resistance in the brain metastatic setting, and future work will test the most promising..."

Metastases • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • PIK3CA

Induction serplulimab and cetuximab combined with chemotherapy followed by radiotherapy for unresectable locally advanced HNSCC: A single-arm, prospective, phase II study (ESMO Asia 2025) - "Patients received serplulimab (4.5 mg/kg, Q3W) + cetuximab (400 mg/m2 loading, followed by 250 mg/m2, QW) + liposomal paclitaxel (135 mg/m2, D1) + cisplatin (75 mg/m2, Q3W), for 3 weeks per cycle, with 2 total treatment cycles. In patients with unresectable LA-HNSCC, this induction regimen showed preliminary efficacy and manageable toxicity. Further follow-up is required to confirm the survival benefit."

Clinical • Metastases • P2 data • Head and Neck Cancer • Hypopharyngeal Cancer • Nasopharyngeal Carcinoma • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients (ASH 2025) - "The most common CAR T-cell products wereaxicabtagene ciloleucel (n = 31, 25%), brexucabtagene autoleucel (n = 26, 21%), and tisagenlecleucel (n =21, 17%)...Nearly all (n = 123; 99%) patients received concurrent dexamethasone (dex) with a median totaldose of 234 mg (range, 30-690)...Sixteen patients (13%)received additional therapies, including ruxolitinib (n = 1), siltuximab (n = 3), cetuximab (n = 1), intrathecalchemotherapy (n = 11), and dasatinib (n = 1)...Higher dex doses remainedassociated with shorter time to ICANS resolution, highlighting that corticosteroids remain thecornerstone of treating refractory ICANS. More effective strategies for anakinra-refractory ICANS arecritically needed."

CAR T-Cell Therapy • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

BI08 A prospective observational study exploring the incidence and impact of cutaneous toxicities in patients undergoing oncological treatment. (PubMed, Br J Dermatol) - "The most frequently observed immunotherapy agent causing cutaneous toxicity was pembrolizumab (20%). Cetuximab and bevacizumab were the most common culprit targeted therapies (both 7%)...Cutaneous toxicities may impact on QoL. Decisions regarding alterations to treatment plans due to cutaneous toxicities should be made in collaboration by oncologists and dermatologist."

Journal • Observational data • CNS Disorders • Dermatology • Eosinophilia • Lung Cancer • Melanoma • Oncology • Psychiatry • Solid Tumor • Steven-Johnson Syndrome

Prevalence of HRAS mutations in metastatic head and neck squamous cell carcinoma: A preliminary study from India (ESMO Asia 2025) - "Tipifarnib, a FTase inhibitor, has been given FDA approval for high VAF HRAS positive HNSCC. HRAS mutations have been shown to have poor response to cetuximab in first-line recurrent metastatic setting... This preliminary study demonstrates a notably high prevalence (20%) of HRAS mutations among Indian patients with metastatic HNSCC highlighting the potential for integrating HRAS-targeted therapies into future clinical management protocols in India."

Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HRAS

Conversion rates to surgery or radiotherapy with neoadjuvant cetuximab-based therapy in locally advanced head and neck squamous cell carcinoma: AI-assisted peripheral immune biomarkers analysis (ESMO Asia 2025) - "In this real-world cohort, neoadjuvant cetuximab-based therapy was directly responsible for a high conversion rate to surgery or RT, perfectly aligning with tumour response. AI/ML-assisted analysis identified baseline NLR and ALC as predictors of response and conversion in HNSCC. This approach can accelerate biomarker discovery and aid personalised treatment planning."

Biomarker • Clinical • Metastases • Surgery • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Radiation-induced upregulation of PD-LI is blunted by acquired resistance to cetuximab and/or ruxolitinib (ESMO Asia 2025) - "Radiation treatment resulted in upregulation of PD-LI for HNSCC cells. Also, EGFR-JAK/STAT signaling is known to play a role in activation of PD-LI. Acquired resistance to the anti-EGFR agent cetuximab and/or the anti-JAK/STAT agent ruxolitinib was found to significantly blunt radiation-induced activation of PD-LI."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Establishing a microfluidic liquid-biopsy platform for prognosticating head and neck cancer with the DS-SACA chip (ESMO Asia 2025) - "With just 2 mL of blood, SACA simultaneously enumerates tumor and immune components in advanced HNSCC. Rising CTC curves reflect tumor burden; CTM-linked CD14+ cells signal resistance and poor prognosis; and cetuximab lowers CD11b+ suppressor cells. SACA therefore offers a rapid, integrated liquid-biopsy readout that has potential to guide personalized therapy."

Biopsy • Liquid biopsy • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CD14 • CTCs • ITGAM • NCAM1 • PTPRC

Cetuximab in maintenance after induction, right-sided tumors, and rechallenge in metastatic colorectal cancer: Insights from real-world practice in India (ESMO Asia 2025) - "Findings support the extended role of cetuximab in line with current ESMO guidelines. This is the first study to report real-world outcomes from Indian population, and demonstrates the potential for flexible anti-EGFR use tailored to patient selection and prior treatment history in mCRC, offering valuable regional insights to global evidence."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Cetuximab combined with chemotherapy in RAS wild-type metastatic colorectal cancer: A real-world study in Indian settings (ESMO Asia 2025) - "In the induction phase, most patients received FOLFOX (67), followed by FOLFIRI (18), with smaller numbers on CAPOX (3), IRIS (1), and 12 missing... This real-world evidence analysis reinforces the established benefit of cetuximab combined with chemotherapy in RAS WT, left-sided mCRC patients. These findings are aligned with the outcomes from major trials such as CALGB 80405 (PFS: 10.45 months) and ASCO 2016 analyses (PFS: 11.4 months). Notably, this is the first such study from the Indian subcontinent, reflecting outcomes in a heterogeneous patient population and adding valuable regional RWD to the global evidence base."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Real-world observational study of fruquintinib in combination with irinotecan and capecitabine as second-line treatment in patients with advanced colorectal cancer (ESMO Asia 2025) - P | "11 (52.4%) and 4 (19.0%) patients had received bevacizumab and cetuximab as part of their first-line treatment. These results show the preliminary efficacy and safety of fruquintinib in combination with irinotecan and capecitabine as a second-line treatment for patients with advanced colorectal cancer."

Clinical • Combination therapy • Metastases • Observational data • Real-world • Real-world evidence • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • UGT1A1

First-line panitumumab versus cetuximab for all RAS wild-type metastatic colorectal cancer: Survival and metastatic-site resection in a Taiwanese Multicenter cohort (ESMO Asia 2025) - "First-line panitumumab and cetuximab achieved similar OS, but panitumumab was consistently associated with higher metastatic-site resection rates. Metastasectomy was linked to markedly prolonged survival, supporting panitumumab's potential in conversion therapy."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • EGFR • RAS

First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study (ESMO Asia 2025) - P3 | "Background: The randomized phase 3 BREAKWATER study (NCT04607421) demonstrated statistically significant and clinically meaningful improvements in ORR by blinded independent central review (BICR), PFS by BICR, and OS with encorafenib + cetuximab (EC) + mFOLFOX6 vs control (chemotherapy ± bevacizumab) in 1L BRAF V600E-mutant mCRC (Kopetz, Nat Med 2025; Elez, N Engl J Med 2025)... Consistent with the global study results, East Asian pts with untreated BRAF V600E-mutant mCRC attained clinically significantly improved ORR, PFS, and OS with EC+mFOLFOX6 vs control therapy. The treatment safety profiles in East Asian pts were consistent with those observed in the overall population and as expected for each agent."

Clinical • Metastases • P3 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF

MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001 (ESMO Asia 2025) - P1 | "In arm 6, pts with advanced CRC and 0-1 prior systemic therapies received MK-1084 (total daily dose 25-100 mg) plus cetuximab 500 mg/m2 Q2W and mFOLFOX6... Updated data continue to show manageable safety profiles and evidence of antitumor activity for MK-1084–based regimens in pts with advanced, KRAS G12C-mutated CRC. The phase 3 KANDLELIT-012 study is evaluating MK-1084 + cetuximab + mFOLFOX as first-line therapy for KRAS G12C-mut advanced CRC."

Metastases • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Colorectal Cancer • Oncology • Solid Tumor

INTERLINK-1: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - P3 | N=370 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Sep 2025 ➔ Sep 2026

Checkpoint inhibition • Trial completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405. (ASCO-GI 2026) - "Funded by National Cancer Institute, Genentech The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for PIK3CA-mutated (mut) metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P1 | "Funded by F. Hoffmann-La Roche Ltd Clinical Trial Registration Number: NCT04929223 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PIK3CA

Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT04224415 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Circulating tumor DNA • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • RAS

Second-line irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT04833036 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P2 data • Colorectal Cancer • Gastrointestinal Cancer • RAS

Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study. (ASCO-GI 2026) - P1/2 | "Funded by Beijing Bethune Charitable Foundation Clinical Trial Registration Number: NCT05775900 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS

T-CORE2401 trial: A randomized phase II trial of mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab as first-line treatment for right-sided, RAS/BRAF wild-type, low-methylated metastatic colon cancer. (ASCO-GI 2026) - "Funded by Tohoku University Hospital, Japan Society of Clinical Oncology (JSCO) Clinical Trial Registration Number: 1021240067 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • RAS

Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD). (ASCO-GI 2026) - P1 | "Funded by ASCO CDA Clinical Trial Registration Number: NCT06358430 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Minimal residual disease • P1 data • Residual disease • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IL15

KANDLELIT-012: Phase 3 study of MK-1084 (a KRAS G12C inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for KRAS G12C-mutant colorectal cancer. (ASCO-GI 2026) - P3 | "Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT06997497 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT06978400 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF